Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04320485 · ClinicalTrials.gov registry record
Evaluation of the Clinical Specificity of the Active Anthrax Detect™ Plus (AAD Plus) Lateral Flow Immunoassay (LFI)
A clinical trial, sponsored by InBios International.
- Completed
- Registry status
- 450
- Enrollment target
NCT04320485 is a clinical trial that has completed, run by InBios International. The registered enrollment target is 450 participants.
The verdict
NCT04320485 has completed, sponsored by InBios International.
- COMPLETED
- Registry status
- 450 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine the estimated clinical specificity of the AAD Plus. A secondary objective is to determine the estimated sensitivity of the AAD Plus as 10% of the study subject samples will be contrived to be positive.
Interventions
- DIAGNOSTIC_TEST Active Anthrax Detect™ Plus (AAD Plus)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2020-03-25 |
| Est. Completion | 2020-12-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04320485
The ClinicalTrials.gov registry entry for NCT04320485 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is InBios International, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Active Anthrax Detect™ Plus (AAD Plus) is the first listed.
NCT04320485 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04320485 about?
NCT04320485 is a clinical study titled "Evaluation of the Clinical Specificity of the Active Anthrax Detect™ Plus (AAD Plus) Lateral Flow Immunoassay (LFI)". The primary objective of the study is to determine the estimated clinical specificity of the AAD Plus. A secondary objective is to determine the estimated sensitivity of the AAD Plus as 10% of the study subject samples will be contrived to be positive.
What is the current status of trial NCT04320485?
This trial is currently completed. The enrollment target is 450 participants. The study started on 2020-03-25. Estimated completion is 2020-12-17.
What interventions are being tested in trial NCT04320485?
The interventions under investigation include: Active Anthrax Detect™ Plus (AAD Plus) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04320485?
This trial is sponsored by InBios International, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.